Ryan A. Metcalf, MD, CQA(ASQ)

Inpatient Chief Value Officer, Department of Pathology
University of Utah Health and ARUP Laboratories
Associate Professor (Clinical), University of Utah School of Medicine

Specialties

• Transfusion medicine
• Clinical pathology

Education

• Medical Degree—University of California Davis School of Medicine
• Residency—Anatomic and Clinical Pathology, Stanford University School of Medicine
• Fellowship—Pathology, Stanford University School of Medicine
• Fellowship—Transfusion Medicine, Stanford University School of Medicine

Certification/Affiliations

• American Board of Pathology (Blood Bank/Transfusion Medicine, Anatomic and Clinical Pathology)

Research Interests

• Data-driven clinical transfusion medicine
• Innovation and data visualization of patient blood management practice performance
• Artificial intelligence in medicine
• Patient blood management
• Quality management
• Risk quantitation of transfusion-related adverse events

Awards

• The William Roberts Award for Excellence in Laboratory Medicine, 2023, Department of Pathology, University of Utah
• Outstanding Teaching Award in Clinical Pathology, 2020, Department of Pathology, University of Utah

Recent Publications

• Carson JL, et al. Red blood cell transfusion: 2023 AABB international guidelines. JAMA. 2023;330(19):1892–902. 
• Li N, et al. Blood demand forecasting and supply management: an analytical assessment of key studies utilizing novel computational techniques. Transfus Med Rev. 2023;37(4):150768.
• White SK, et al. The incidence of transfusion related acute lung injury using active surveillance: A systematic review and meta-analysis. Transfusion. 2023. [Published online ahead of print Dec 2023]
• Walker BS, et al. Meta-analysis of bacterial growth characteristics in platelet components: refining the inputs of a simulation analysis comparing the relative safety of testing strategies. Transfusion. 2023;63(9):1719–27.
• Metcalf RA, et al. Current advances in 2022: a critical review of selected topics by the Association for the Advancement of Blood and Biotherapies (AABB) Clinical Transfusion Medicine Committee. Transfusion. 2023;63(8):1590–600.
• Karafin MS, et al. Antibody titers in transfusion medicine: a critical reevaluation of testing accuracy, reliability, and clinical use. Arch Pathol Lab Med. 2023;147(12):1351–9.
• Walker BS, et al. Bacterial culture time to detection in platelet components: an evidence synthesis and estimation of detection failures. Transfusion. 2023;63(1):182–92.
• White SK, et al. The epidemiology of transfusion-related acute lung injury: a scoping review and analysis. Transfusion. 2023;63(1):104–16.
• Potter S, et al. Life threatening platelet transfusion refractoriness due to an anamnestic human leukocyte antigen alloantibody response. Transfusion. 2022;62(11):2161–2.
• Estcourt LJ, et al. Clinical practice guidelines from the Association for the Advancement of Blood and Biotherapies (AABB): COVID-19 convalescent plasma. Ann Intern Med. 2022;175(9):1310–21.
• Metcalf RA, et al. Current advances in transfusion medicine 2021: A critical review of selected topics by the AABB Clinical Transfusion Medicine Committee. Transfusion. 2022;62(7):1435–45.
• Bloch EM, et al. How do I implement an outpatient program for the administration of convalescent plasma for COVID-19? Transfusion. 2022;62(5):933–41.
• Wang Z, et al. Development and validation of a machine learning method to predict intraoperative red blood cell transfusions in cardiothoracic surgery. Sci Rep. 2022;12(1):1355.
• Fennell K, et al. New ABO intron 1 variant alleles. Immunohematology. 2021;37(4):178–84.
• Benson AE, et al. Transfusion preparedness on labor and delivery: an initiative to improve safety and cost. Obstet Gynecol. 2021;138(5):788–94.
• Allen ES, et al. Current advances in transfusion medicine 2020: a critical review of selected topics by the AABB Clinical Transfusion Medicine Committee. Transfusion. 2021;61(9):2756–67.
• Lin H, et al. Sanguine: Visual analysis for patient blood management. Information Visualization, 2021;20(2-3):123–37.
•  Corean J, et al. Platelet component false positive detection rate in aerobic and anaerobic primary culture: a systematic review and meta-analysis. Transfus Med Rev. 2021;35(3):44–52.
•  Moore RA, et al. In reply: window periods for secondary bacterial culture of platelets according to FDA Guidance. Transfusion. 2021;61(4):1343-4.
•  Karafin MS, et al. Heterogeneity in approaches for switching from universal to patient ABO type-specific blood components during massive hemorrhage: an international survey and review of the literature. Arch Pathol Lab Med. 2021;145(12):1499–504.
•  Self WH, et al. Passive immunity trial for our nation (PassITON): study protocol for a randomized placebo-control clinical trial evaluating COVID-19 convalescent plasma in hospitalized adults. Trials. 2021;22(1):221.
•  Silva O, et al. Classic Hodgkin lymphoma in Guatemalan children of age less than six years: analysis of immune regulatory pathways and the tumor microenvironment. Leuk Lymphoma. 2021;62(7):1609–18.
•  Cohn CS, et al. COVID-19 convalescent plasma: interim recommendations from the AABB. Transfusion. 2021;61(4):1313–23.
•  Metcalf RA, et al. Electronic clinical decision support: evidence that default settings influence end user behavior. Transfusion. 2021;61(3):669-70.
•  Moore RA, et al. The impact of the sample time of secondary bacterial culture on the risk of exposure to contaminated platelet components: a mathematical analysis. Transfusion. 2021;61(3):873–82.
•  Luetkens T, et al. Successful transfer of anti-SARS-CoV-2 immunity using convalescent plasma in a multiple myeloma patient with hypogammaglobulinemia and COVID-19. Blood Adv. 2020;4(19):4864–8.
•  Corean J, et al. The incremental benefit of anaerobic culture for controlling bacterial risk in platelets: a systematic review and meta-analysis. Vox Sang. 2021;116(4):397–404.
•  Walker BS, et al. Residual bacterial detection rates following primary culture as determined by secondary culture and rapid testing in platelet components: a systematic review and meta-analysis. Transfusion. 2020;60(9):2029–37.
•  Walker BS, et al. The comparative safety of bacterial risk control strategies for platelet components: a simulation study. Transfusion. 2020;60(8):1723–31.
•  Pagano MB, et al. Current advances in transfusion medicine: a 2019 review of selected topics from the AABB Clinical Transfusion Medicine Committee. Transfusion. 2020;60(7):1614–23.
•  White SK, et al. Bacterial contamination rate of platelet components by primary culture: A systematic review and meta-analysis. Transfusion. 2020;60(5):986–96.
•  Lim MY, et al. Things we do for no reason: routinely prescribing transfusion premedication to prevent acute transfusion reactions. Journal of Hospital Medicine. 2020;15(11):684–6.
•  Gavva C, et al. Response to random apheresis platelets versus HLA-selected platelets versus pooled platelets in HLA-sensitized patients. Transfusion. 2019;59(7):2276–81.
•  Metcalf RA, et al. The association of inpatient blood utilization and diagnosis related group weight: implications for risk-adjusted benchmarking. Transfusion. 2019;59(7):2316–23.
•  Pagano MB, et al. Evaluating safety and cost-effectiveness of platelets stored in additive solution (PAS-F) as a hemolysis risk mitigation strategy. Transfusion. 59(4):1246–51.
•  Metcalf RA, et al. Severe hemolysis following extracorporeal right ventricular assist device placement. Transfusion. 2019;59(4): 1178–9.
•  Murphy C, et al. Transfusion associated chest pain. Transfusion. 2019;59(2):463–9.
•  Metcalf RA, et al. Severe ABO hemolytic disease of the newborn requiring exchange transfusion. J Pediatr Hematol Oncol. 2019;41(8):632–4.